Skip to Content

Xadago (safinamide) Disease Interactions

There are 5 disease interactions with Xadago (safinamide):

Major

Dopamine Agonists (Includes Xadago) ↔ Hypotension

Severe Potential Hazard, Moderate plausibility

Applies to: Hypotension

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.

References

  1. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.
  3. Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol 30 (1990): 194-9
  4. "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim, Ridgefield, CT.
  5. Hoehn MM "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol 32 (1975): 50-1
  6. "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.
View all 6 references
Major

Dopaminergic Antiparkinson Agents (Includes Xadago) ↔ Psychosis

Severe Potential Hazard, Moderate plausibility

Applies to: Psychosis

Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.

Major

Safinamide (Includes Xadago) ↔ Hepatic Impairment

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Safinamide is contraindicated in patients with severe hepatic dysfunction (Child-Pugh C). In patients with moderate hepatic impairment the maximum recommended dose is 50 mg orally once a day. If a patient taking this dose progresses from moderate to severe hepatic impairment, safinamide should be discontinued.

Moderate

Safinamide (Includes Xadago) ↔ Hypertension

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypertension

Safinamide may cause hypertension or exacerbate existing hypertension. Patients should be monitored for new onset hypertension or hypertension that is not adequately controlled after starting treatment. Dosage adjustment may be necessary if elevation of blood pressure is sustained.

Moderate

Safinamide (Includes Xadago) ↔ Retinal Pathology

Moderate Potential Hazard, Moderate plausibility

Applies to: Retinal Disorder, Uveitis

Animal studies with safinamide showed retinal degeneration, loss of photoreceptor cells, cataracts, and retinal scarring. Patients should be periodically monitored for visual changes, especially if they have a history of retinal/macular degeneration, uveitis, inherited retinal conditions, family history of retinal disease, albinism, retinitis pigmentosa, or active retinopathy (e.g., diabetic retinopathy).

Xadago (safinamide) drug Interactions

There are 706 drug interactions with Xadago (safinamide)

Xadago (safinamide) alcohol/food Interactions

There are 2 alcohol/food interactions with Xadago (safinamide)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide